VEGFA and diabetic retinopathy: Recently, intraocular injection of anti-VEGF agents to prevent neovascularization is usual worldwide for the treatment of diabetic retinopathy, age-related macular degeneration, etc. On the other hand, we recently developed a AAV vector which can prevent the progress of neurodegeneration in mouse models of glaucoma [35].